Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 9, 2006, Pages 1381-1387

  Ji, Sangwon ^a   Hyun, Soo Kim ^d   Jae, Woo Kim ^a   Myeong, Kwan Jee ^a   Kwang, Wha Park ^a   Uh, Young ^a   Dong, Ki Lee ^b   Jae, Suk Song ^c   Soon, Koo Baik ^a   Sang, Ok Kwon ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kwandong University College of Medicine   (South Korea)

^d Wonju Severance Christian Hospital   (South Korea)

Author keywords

CYP2C19 genotype; Healing rapidity; Omeprazole; Peptic ulcer; Rabeprazole

Indexed keywords

ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2C19; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; MISOPROSTOL; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SUCRALFATE;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DUODENUM ULCER; FEMALE; GENOTYPE; HEADACHE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PEPTIC ULCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH ULCER; ULCER HEALING;

EID: 33746595230     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04314.x     Document Type: Article

References (38)

1. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
2. +-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem. Pharmacol. 1990; 29: 661-7.
3. Fujisaki H, Shibata H, Oketani K et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem. Pharmacol. 1991; 42: 321-8.
4. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thio reagents. J. Biol. Chem. 1997; 272: 22438-16.
5. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol. Ther. 1998; 12: 1079-89.
6. Dekkers CPM, Beker JA, Thjodleifsson B et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - European multicentre study. Aliment Pharmacol. Ther. 1998; 12: 789-95.
7. Dekkers CPM, Beker JA, Thjodleifsson B et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol. Ther. 1998; 13: 179-86.
8. Adachi K, Katsube T, Kawamura A et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol. Ther. 2000; 14: 1259-66.
9. Horai Y, Kimura M, Furuie H et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol. Ther. 2001; 15: 793-803.
10. Furuta T, Ohashi K, Kosuge K et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 1999; 65: 552-61.
11. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. 1996; 31: 9-28.
12. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole. Aliment Pharmacol. Ther. 1999; 13 (Suppl. 3): 27-36.
13. Ohning GY, Barbuti RC, Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol. Ther. 2000; 14: 701-8.
14. Williams MP, Blanshard C, Millson C, Sercombe J, Pounder RE. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol. Ther. 2000; 14: 691-9.
15. Shim CS, Cho JY, Chung IS et al. Rabeprazole 10 mg versus omeprazole 20 mg in the treatment of duodenal ulcer: the Korean multicenter, comparative trial (in Korean with English abstract). Korean J. Gastrointest Endosc. 2002; 24: 76-83.
16. Kim HS, Lee DK, Baik SK, Seo JI, Kwon SO. Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer. J. Gastroenterol. 2001; 36: 96-102.
17. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 1984; 269: 419-22.
18. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 1984; 46: 594-8.
19. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression in healing duodenal ulcer? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
20. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol. Ther. 1990; 2: 25-33.
21. Howden CW, Jones DB, Peace KE, Burget DW, Hunt RH. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates. Dig. Dis. Sci. 1988; 33: 619-24.
22. Sakai T, Aoyama N, Kita T et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm. Res. 2001; 18: 721-7.
23. Ando T, Kato H, Kajikawa H et al. Comparison of the influence of CYP2C19 polymorphism on the effect of rabeprazole and omeprazole during the early healing phase of gastric ulcer (Abstract). Gastroenterology 2002; 122: A514.
24. Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br. J. Clin. Pharmacol. 1990; 29: 557-63.
25. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 1984; 36: 773-80.
26. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 1996; 60: 661-6.
27. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur. J. Clin. Pharmacol. 1988; 35: 167-71.
28. Edeki TI, Goldstein JA, de Morais SMF et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 1996; 6: 357-60.
29. Bertilsson L, Lou Y-Q, Du Y-L et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 1992; 51: 388-97.
30. Horai Y, Nakano M, Ishizaki T et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 1989; 46: 198-207.
31. Sohn D-R, Kusaka M, Ishizaki T et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmaco-kinetics. Clin. Pharmacol. Ther. 1992; 52: 160-9.
32. Hosking SW, Ling TK, Chung SC et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994; 343: 508-10.
33. Lam SK, Ching CK, Lai KC et al. Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. Gut 1997; 41: 43-8.
34. Sung JJ, Chung SC, Ling TK et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N. Engl. J. Med. 1995; 332: 139-42.
35. Marshall BJ, Goodwin CS, Warren JR et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437-12.
36. Penston JG. Clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Aliment Pharm. Ther. 1996; 10: 469-86.
37. Kirwan JR, Barnes CG, Davies PG, Currey HL. Analysis of clinical judgment helps to improve agreement in the assessment of rheumatoid arthritis. Ann. Rheum Dis. 1988; 47: 138-43.
38. Saunders MB, Gulabivala K, Holt R, Kahan RS. Reliability of radiographic observations recorded on a proforma measured using interand intra-observer variation: a preliminary study. Int. Endod J. 2000; 3: 272-8.